Ending Specialized Follow-Up Feasible in Asymptomatic, Low-Risk Leukemia
THURSDAY, April 18, 2024 -- For select patients with asymptomatic, lower-risk chronic lymphocytic leukemia, ending specialized follow-up (sFU) is feasible and safe, according to a study published in the March 1 issue of Blood Advances.Christian... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2024 Category: Pharmaceuticals Source Type: news
Can Older Patients With Low-Risk Leukemia Quit Seeing Specialists?
TUESDAY, April 8, 2024 -- Some slow-growing cases of leukemia don ’t need constant surveillance by cancer specialists, a new study claims.Low-risk patients with slow-growing chronic lymphocytic leukemia (CLL) and no symptoms fared well even after... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2024 Category: General Medicine Source Type: news
FDA Approves First CAR-T for Chronic Lymphocytic Leukemia
(MedPage Today) -- The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers Squibb announced on Thursday... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 15, 2024 Category: American Health Source Type: news
U.S. FDA Approves Bristol Myers Squibb ’s Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
PRINCETON, N.J.--(BUSINESS WIRE) Mar 14, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 14, 2024 Category: Drugs & Pharmacology Source Type: news
Why I Stopped Being A “Good” Cancer Patient
“You are allergic to your oral chemotherapy,” explains my oncology team at a recent appointment. “We are going to try a newer drug,” I am on my fourth attempt to find an oral treatment suitable for both my body and my cancer, so that I can maintain a remission that took three years and a stem cell transplant to achieve. “We want to get ahead of it before it gets ahead of us.” In my headphones, Weezer achingly croons, “Say it ain’t so, your drug is a heartbreaker.”
[time-brightcove not-tgx=”true”]
Since being diagnosed with phase three chronic myeloid leu...
Source: TIME: Health - February 6, 2024 Category: Consumer Health News Authors: Walela Nehanda Tags: Uncategorized freelance Source Type: news
All-Oral Therapy Promising in Higher-Risk MDS, CMML
(MedPage Today) -- An all-oral combination therapy appeared to show promising activity for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with acceptable safety, according to results from a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 5, 2024 Category: Hematology Source Type: news
Chronic Lymphocytic Leukemia Highlights From ASH 2023 Chronic Lymphocytic Leukemia Highlights From ASH 2023
Doublet and triplet therapies as well as strong results from late-generation BTK inhibitors and sequencing are among CLL highlights from ASH 2023, as reported by Dr John Allan.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
FDA Approves Label Update for Brukinsa (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of Brukinsa versus Imbruvica® (ibrutinib) in Relapsed or Refractory CLL
ALPINE is the only Phase 3 Bruton’s tyrosine kinase... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 22, 2023 Category: Drugs & Pharmacology Source Type: news
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
WEDNESDAY, Dec. 13, 2023 -- For patients with chronic lymphocytic leukemia (CLL), measurable residual disease (MRD)-directed ibrutinib-venetoclax treatment improves progression-free and overall survival, according to a study published online Dec.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 13, 2023 Category: Pharmaceuticals Source Type: news
Measurable Residual Disease-Guided Therapy Promising in CLL Measurable Residual Disease-Guided Therapy Promising in CLL
The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
'New Gold Standard' for Previously Untreated CLL
(MedPage Today) -- SAN DIEGO -- A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2023 Category: Hematology Source Type: news
Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients
(MedPage Today) -- SAN DIEGO -- A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2023 Category: Hematology Source Type: news
Non-Covalent BTK Inhibitor Approved for CLL
(MedPage Today) -- The FDA expanded the label of pirtobrutinib (Jaypirca) to include the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) following two prior lines of therapy, the agency announced on Friday.
An... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 4, 2023 Category: Hematology Source Type: news
Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition
In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2023 Category: Drugs & Pharmacology Source Type: news
First in human trial of new drug raises hopes for patients with relapsed blood cancer
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments. (Source: World Pharma News)
Source: World Pharma News - November 6, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
